All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2005-001315-22||The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age.||2009-07-31||due-trials|
|Ongoing||2005-001722-92||Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)||not-yet-due|
|Not reported||2006-001385-16||Rheohemapheresis and Lutein Supplementation (xantophyll carotenoid) in the Non-Exsudative Form of Age-Related Macular Degeneration. (ReLux-AMD)||2012-02-08||due-trials|
|Not reported||2006-001389-18||Comparison of Combined Therapy of Intravitreal Injection of Bevacizumab and Pegaptanib versus Mono-therapy (The MAAM Study)||2008-03-31||due-trials|
|Ongoing||2006-006760-28||Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to Ag...||not-yet-due|
|Ongoing||2007-005157-33||A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Multicenter An...||not-yet-due|
|Completed, but no date||2007-006288-56||Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis||bad-data|
|Reported results||2011-004152-19||Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial||2016-01-18||due-trials|